Single nucleotide polymorphism rs2596542 and MICA/B expression in nasopharyngeal carcinoma
Main Article Content
Abstract
Major histocompatibility complex class I chain-related A/B (MICA/B) are tumor antigens.
MICA/B are greatly expressed in human on the surface of malignant cancerous cells and trigger
immune system response. This study was conducted to identify the genetic variant rs2596542
C>T in regulating MICA/B expression in nasopharyngeal carcinoma (NPC). A total of 58 tumor
tissues from nasopharyngeal carcinoma patients were examined in this study. Single nucleotide
polymorphism (SNP) association was determined by genotyping real-time PCR. MICA/B protein
expression was quantified by performing immunohistochemistry staining. Tumors derived from CC
genotype had the lowest MICA/B expression (p = 0.03). Tumors derived from rs2596542T allele
had greater MICA/B expression levels than those with tumors with the rs2596542C allele (p =
0.04). Levels of MICA/B expression in NPC tissue were highly correlated with the patients who
carried the T allele of rs2596542. The high-risk T allele of rs2596542 on the MICA gene and level
of MICA/B protein expression can become potential targets for immunotherapy treatment in NPC.
Article Details
Keywords
nasopharyngeal carcinoma, MICA/B expression, rs2596542
References
2. Lee AWM, Ng WT, Chan LLK, et al. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;110(3):377-384. doi: 10.1016/j.radonc.2014.02.003.
3. Wu F, Wang R, Lu H, et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;112(1):106-111. doi: 10.1016/j.radonc.201 4.05.005.
4. Zong J, Lin S, Lin J, et al. Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma: Validation of the 7th edition AJCC staging system. Oral Oncol. 2015;51(3):254-259. doi: 10.1016/j.oraloncolo gy.2014.10.012.
5. Lin S, Pan J, Han L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;110(3):385-389. doi: 10.1016/j.radonc.20 14.01.011.
6. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376. doi: 10.1016/s0065-2776(08)60664-1.
7. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025-1036. doi: 10.1038/ni.3518.
8. Jinushi M, Takehara T, Tatsumi T, et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol. 2005;43(6):1013-1020. doi: 10.1016/j.jhep.2005.05 .026.
9. Lynn TC, Wang JH, Yang CS, Tu SM. [Natural killer cell activity in patients with nasopharyngeal carcinoma]. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1986;19(3):177-182.
10. Kuang XJ, Mo DC, Qin Y, et al. Single nucleotide polymorphism of rs2596542 and the risk of hepatocellular carcinoma development. Medicine (Baltimore). 2019;98(11):e14767. doi: 10.1097/MD.0000000000014767.
11. Kumar V, Kato N, Urabe Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011; 43(5):455-458. doi: 10.1038/ng.809.
12. Nguyễn PT, Vũ HL, Nguyễn VC, et al. Nghiên cứu xác định đa hình đơn Nucleotide RS2596542 của gen mica ở bệnh nhân ung thư vòm họng. 2021;05(03). doi: 10.38148/JHDS.0503SKPT21-012.
13. Zhang J, Basher F, Wu JD. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin. Front Immunol. 2015;6:97. doi: 10.3389/fimmu.2015.00097.
14. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol Baltim Md 1950. 2002;169(8):4098-4102. doi: 10.4049/jimmunol.169.8.4098.
15. Ben Chaaben A, Ouni N, Douik H, et al. Soluble MICA and anti-MICA Antibodies as Biomarkers of Nasopharyngeal Carcinoma Disease. Immunol Invest. 2020;49(5):498-509. doi: 10.1080/08820139.2019.1690506.
16. Tong HV, Toan NL, Song LH, Bock CT, Kremsner PG, Velavan TP. Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. J Viral Hepat. 2013;20(10):687-698. doi: 10.1111/jvh.12089.
17. Kumar V, Yi Lo PH, Sawai H, et al. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PloS One. 2012;7(9):e44743. doi: 10.1371/journal.pone. 0044743.
18. Xing S, Ferrari de Andrade L. NKG2D and MICA/B shedding: a “tag game” between NK cells and malignant cells. Clin Transl Immunol. 2020;9(12):e1230. doi: 10.1002/cti2. 1230.
19. Isernhagen A, Schilling D, Monecke S, et al. The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA. Immunogenetics. 2016;68:109-123. doi: 10.1007/s00251-015-08 84-8.
20. Luo X, Wang Y, Shen A, Deng H, Ye M. Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis. BMC Med Genet. 2019;20(1):142. doi: 10.1186/s12881-019-087 1-2.
21. Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res. 2017;8(4):343-349. doi: 10.1016/j.jare.2017.03.004.